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Increased prevalence of subclinical and clinical hypothyroidism
in persons with chronic kidney disease.
Background. Previous studies have suggested a higher preva-
lence of thyroid abnormalities in persons with end-stage renal
disease. However, little is known regarding the epidemiology of
thyroid disorders in persons with less severe kidney dysfunction.
Methods. We used data from the Third National Health and
Nutrition Examination Survey to examine the prevalence of hy-
pothyroidism (clinical and subclinical) at different levels of esti-
mated glomerular filtration rate (GFR). We used multivariable
logistic regression to evaluate the association between GFR and
prevalent hypothyroidism.
Results. Among 14,623 adult participants with serum cre-
atinine and thyroid function test results, the mean age was
48.7 years, and 52.6% were women. The prevalence of hy-
pothyroidism increased with lower levels of GFR (in units of
mL/min/1.73m2), occurring in 5.4% of subjects with GFR ≥90,
10.9% with GFR 60–89, 20.4% with GFR 45–59, 23.0% with
GFR 30–44, and 23.1% with GFR <30 (P < 0.001 for trend).
Overall, 56% of hypothyroidism cases were considered subclin-
ical. Compared with GFR ≥90 mL/min/1.73m2, reduced GFR
was associated with an increased risk of hypothyroidism, after
adjusting for age, gender, and race/ethnicity: adjusted odds ratio
1.07 (95% confidence interval: 0.86–1.32) for GFR 60–89, 1.57
(1.11–2.22) for GFR 45–59, 1.81 (1.04–3.16) for GFR 30–44,
and 1.97 (0.69–5.61) for GFR <30 mL/min/1.73m2 (P = 0.008
for trend).
Conclusion. Among a nationally representative sample of
adults, reduced glomerular filtration rate was associated with
a higher prevalence of hypothyroidism, with many subclinical
cases. Future studies are needed to determine the potential ad-
verse effects of subclinical and clinical hypothyroidism in per-
sons with chronic kidney disease.
Despite considerable overlap in the symptoms related
to hypothyroidism and advanced chronic kidney disease
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(CKD) (e.g., fatigue, lethargy, cognitive and sexual dys-
function), relatively little is known about the prevalence
or severity of thyroid abnormalities in persons with CKD.
Increased prevalence of goiter [1, 2] and thyroid gland
volume [3] have been reported in patients with end-stage
renal disease (ESRD), and it has been suggested that pri-
mary hypothyroidism may be more common in patients
with ESRD compared with the general population [2]. In
addition, thyroid hormone abnormalities have been re-
ported among euthyroid patients with ESRD, including
reduced total and free triiodothyronine (T3) and thyrox-
ine (T4) levels [2, 4–6]. Reasons for these latter findings
are unclear, but it has been postulated to be due, at least
in part, to an adaptive response to chronic nonthyroidal
illness, unresolved uremia, and protein malnutrition [4].
Despite the growing literature about other metabolic
and hormonal abnormalities that begin at much milder
degrees of renal insufficiency [7], little is known about
thyroid abnormalities or related adaptations in persons
with CKD who do not require maintenance dialysis.
To explore this question, we examined data from the
Third National Health and Nutrition Examination Sur-
vey (NHANES III), a nationally representative sample
of the United States population, to determine the preva-
lence of hypothyroidism at different levels of kidney func-
tion. We hypothesized that the prevalence of thyroid
abnormalities would be increased in persons with CKD
relative to otherwise healthy individuals.
METHODS
Study population
The National Center for Health Statistics conducted its
third national survey (NHANES III) from 1988 through
1994, which was designed to provide national estimates
of the health and nutritional status of civilian, nonin-
stitutionalized individuals in the United States [8]. The
survey was achieved using a multistage sampling plan,
with oversampling of older persons, blacks, and Mexi-
can Americans in order to obtain reliable estimates in
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these subgroups. Subjects were examined in a mobile ex-
amination center or at their place of residence. Informa-
tion was collected on age, sex, self-reported race/ethnicity
(predefined as non-Hispanic white, non-Hispanic black,
Mexican American, or other), body size and composition,
comorbid conditions, laboratory studies, and medication
use.
For these analyses, we excluded subjects who were
younger than 21 years of age, women who were pregnant
(given potential pregnancy-related changes in thyroid
function), subjects who were receiving concurrent treat-
ment with drugs that could contribute to hypothyroidism
(lithium, amiodarone, or iodine, N = 36), and subjects
receiving antithyroid drugs (methimazole or propylth-
iouracil, N = 10), presumably for hyperthyroidism. We
also excluded subjects in whom kidney function could not
be estimated due to missing serum creatinine values or
demographic variables (age, gender, and race/ethnicity),
or those in whom thyroid-stimulating hormone (TSH)
levels were not available (N = 3523).
Laboratory measures
All NHANES III participants over age 12 years who
were examined in the mobile examination center were
eligible for measurement of serum creatinine, TSH, total
thyroxine (total T4), and thyroid peroxidase (TPO) anti-
bodies. As previously described [9], TSH was measured
by chemiluminescence immunometric assay (Nichols In-
stitute Diagnostics, San Juan Capistrano, CA, USA), to-
tal thyroxine by radioimmunoassay, and TPO antibody
by direct radioimmunoassay (Kronus, Dana Point, CA,
USA) in the USC Thyroid Clinical Laboratory. The nor-
mal reference range for TSH was 0.39 to 4.60 mIU/L,
for total T4, 4.5 to 13.2 lg/dL, and for TPO antibody,
<0.5 IU/mL.
Assessment of kidney function and prevalent
hypothyroidism
We estimated glomerular filtration rate (GFR) us-
ing the abbreviated Modification of Diet in Renal Dis-
ease (MDRD) equation [GFR(mL/min/1.73m2) = 186 ×
(serum creatinine [mg/dL])−1.154 × (age years])−0.203 ×
(0.742 if female) × (1.21 if African American)] [10, 11],
and appropriately calibrated serum creatinine as previ-
ously described [12, 13]. Subjects were initially classi-
fied as having either an estimated GFR ≥60 or <60 mL/
min/1.73m2 because previous studies have shown that
metabolic abnormalities associated with CKD (such as
decreased hemoglobin level) become apparent around
this GFR level [7, 14, 15]. Secondary analyses were per-
formed using a modification of the National Kidney Foun-
dation CKD staging based on estimated GFR categories
of≥90, 60 to 89, 45 to 59, 30 to 44, and<30 mL/min/1.73m2
[15].
Hypothyroidism was defined as a TSH level
>4.5 mIU/L [9] or treatment with thyroid hormone
(levothyroxine, liothyronine sodium, thyroid). Subclin-
ical hypothyroidism was defined by a TSH >4.5 mIU/L
and total T4 ≥4.5 lg/dL (the lower limit of the normal
range) [9]. The laboratory criteria for hypothyroidism
(including subclinical hypothyroidism) are based on
those established for previous analyses of thyroid disease
prevalence within NHANES III by Hollowell et al [9].
Covariates
Covariates such as age, gender, and race/ethnicity were
assessed based on patient self-report. We also identified
participants who were likely to have type 1 diabetes mel-
litus, as previously described [16] (i.e., diagnosed with di-
abetes younger than 30 years of age or continuous use of
insulin), because type 1 diabetes mellitus is known to be
associated with both the exposure (CKD) and outcome
(hypothyroidism).
Statistical analyses
Continuous variables were compared among persons
with and without hypothyroidism using Student t test (or
the Wilcoxon rank sum test for non-normally distributed
data), and categorical variables were compared using the
chi-square test. We calculated the point prevalence of hy-
pothyroidism with associated 95% confidence intervals
at different levels of kidney function. We evaluated the
prevalence of hypothyroidism across the spectrum of esti-
mated GFR using the Cochrane-Armitage test. To adjust
for the residual effects of age, sex, and race (variables
embedded in the equation for estimating GFR), we per-
formed logistic regression analysis using hypothyroidism
as the dependent variable. We examined the independent
relation between GFR and hypothyroidism using two ap-
proaches. First, we compared estimated GFR <60 versus
≥60 mL/min/1.73m2. Next, we examined GFR categories
based on the modified National Kidney Foundation CKD
categories with a test for trend. We controlled for age as
a confounder because age is associated with both CKD
and hypothyroidism. We adjusted for age as a linear and
as a quadratic term in the overall model and conducted
stratified models for age ≤70 versus >70 years.
In addition, because severe hypothyroidism has been
reported to cause reversible increases in serum creatinine
concentrations [17, 18], which may lead to an underesti-
mation of true GFR, we repeated analyses after excluding
persons with TSH ≥30 mIU/L. Finally, we examined the
relation between GFR and biochemical evidence of hy-
pothyroidism after excluding persons who were receiving
thyroid hormone treatment to address potential concerns
that selected individuals might have received thyroid hor-
mone treatment for reasons other than hypothyroidism.
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Table 1. Characteristics of NHANES III participants with and without prevalent subclinical or clinical hypothyroidism (unweighted data in
14,623 total individuals)
Hypothyroidisma No Hypothyroidism
Characteristic (N = 1162) (N = 13,461) P valueb
Age years, mean ± SD 61.2 ± 17.5 47.7 ± 18.6 <0.0001
Women, N% 812 (69.9%) 6859 (51%) <0.0001
Race/ethnicity <0.0001
Non-Hispanic white 711 (61.2%) 5459 (40.6%)
Non-Hispanic black 142 (12.2%) 3771 (28.0%)
Mexican American 273 (23.5%) 3677 (27.3%)
Other 36 (3.1%) 554 (4.1%)
TSH level mIU/L, median [25th, 75th] 5.30 [2.32, 7.7]c 1.41 [0.99, 2.1] <0.0001
Total T4 lg/dL, mean ± SD 8.7 ± 3.0 8.8 ± 2.0
TPO antibody ≥0.5 IU/mL, N% 634 (54.6%) 1329 (9.9%) <0.0001
Type 1 diabetes mellitus, N% 1 (0.1%) 19 (0.1%)
Estimated GFR mL/min/1.73m2 <0.0001
≥90 517 (44.5%) 9045 (67.2%)
60–89 450 (38.7%) 3689 (27.4%)
45–59 133 (11.4%) 520 (3.9%)
30–44 47 (4.0%) 157 (1.2%)
<30 15 (1.3%) 50 (0.4%)
Abbreviations are: TSH, thyroid stimulation hormone; T4, thyroxine; TPO, thyroid peroxidase; GFR, estimated glomerular filtration rate.
aSubclinical and clinical hypothyroidism defined as TSH >4.5 (N = 811) or treatment with thyroid medication. A total of 655 persons not receiving thyroid medication
had subclinical hypothyroidism, based on a TSH level >4.5 mIU/L and total T4 ≥4.5 lg/dL.
bP values obtained from Student t test for continuous variables (with the exception of Mann-Whitney test for TSH level) or chi-squared test for categorical variables.
cThe median TSH level among persons not receiving thyroid medication was 6.1 (interquartile range: 5.2 to 8.9).
Statistical analyses were conducted using SAS statisti-
cal software version 8.2 (SAS Institute, Cary, NC, USA)
and Stata 8.2 (Stata Corp., College Station, TX, USA). A
two-tailed P value less than 0.05 was considered statisti-
cally significant. Because NHANES III was not a random
sample of the United States population, appropriate sam-
ple weights were used to obtain weighted regression esti-
mates from the sampled population. The sample weights
were also adjusted for noncoverage and nonresponse [19,
20]. The final results are thus broadly generalizable to the
United States population.
RESULTS
Study population
A total of 14,623 NHANES III adult participants had
valid serum creatinine measurements, estimated GFR,
and thyroid stimulating hormone values, and no exclu-
sion criteria. The mean age was 48.7 ± 18.9 years. There
were 7671 women and 6952 men. A total of 42.2% were
non-Hispanic white, 26.8% non-Hispanic black, 27.0%
Mexican American, and 4.0% with other race/ethnicity,
reflecting the intended sampling strategies of NHANES
III.
Characteristics of persons with and without
prevalent hypothyroidism
Overall, individuals with clinical and subclinical hy-
pothyroidism were on average 14 years older, and more
likely to be women and non-Hispanic whites (Table 1).
The median TSH level was significantly higher in the hy-
pothyroid group (5.30 vs. 1.41 mIU/L, P < 0.0001), and as
expected, there was a much higher proportion of individ-
uals with an elevated thyroid peroxidase antibody level in
this group (54.6% vs. 9.9%, P < 0.0001). Among the 733
individuals with TSH >4.5 mIU/L who were not receiving
thyroid hormone treatment, 655 (89%) had evidence of
subclinical hypothyroidism. Persons with subclinical hy-
pothyroidism were slightly younger (60.0 ± 18.5 vs. 62.7 ±
16.0 years, P = 0.01), and less likely to be female (62.4
vs. 79.5%, P < 0.001), but had no significant difference
in estimated GFR compared with persons with presumed
clinical hypothyroidism. Total T4 concentrations did not
differ significantly between the hypothyroid and nonhy-
pothyroid groups, largely due to the high percentage of
subclinical cases among persons with untreated hypothy-
roidism.
Kidney function and prevalent hypothyroidism
We observed that the prevalence of hypothyroidism
was increased in persons with reduced GFR, ranging
from 5.4% for persons with estimated GFR ≥90 mL/
min/1.73m2 to more than 20% in persons with estimated
GFR <60 mL/min/1.73m2 (Fig. 1). After adjusting for
age, sex, and race/ethnicity, compared with estimated
GFR ≥60 mL/min/1.73m2, GFR <60 mL/min/1.73m2 was
associated with an increased odds of hypothyroidism
[adjusted odds ratio (OR) 1.58 (95% CI: 1.16 to 2.14)].
Compared with GFR ≥90 mL/min/1.73m2 , the adjusted
odds of hypothyroidism increased among subjects with
lower estimated GFR: adjusted OR 1.07 (95% CI: 0.86
to 1.32) for GFR 60 to 89 mL/min/1.73m2, 1.57 (1.11 to
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Fig. 1. Prevalence of hypothyroidism by
level of estimated glomerular filtration rate.
Error bars represent 95% confidence limits.
Numbers in parentheses denote the number
of persons in each category of glomerular fil-
tration rate. P < 0.0001 for trend.
2.22) for GFR 45 to 59 mL/min/1.73m2, 1.81 (1.04 to
3.16) for GFR 30 to 44 mL/min/1.73m2, and 1.97 (0.69
to 5.61) for GFR <30 mL/min/1.73m2 (P = 0.008 for
trend). After excluding the 42 (3.6%) persons with a TSH
≥30 mIU/L, lower GFR remained a significant predictor
of prevalent hypothyroidism (data not shown). Lower
GFR also remained a significant predictor of prevalent
hypothyroidism in companion analyses that excluded per-
sons who were receiving thyroid hormone treatment (N =
429): adjusted OR 1.30 (95% CI: 1.00 to 1.70) for GFR
60 to 89 mL/min/1.73m2, 2.30 (1.50 to 3.53) for GFR 45
to 59 mL/min/1.73m2, 2.38 (1.07 to 5.31) for GFR 30
to 44 mL/min/1.73m2, and 1.72 (0.63 to 4.70) for GFR
<30 mL/min/1.73m2 (P < 0.001 for trend).
We conducted companion analyses stratified by age
≤70 vs. >70 years given the strong associations among
older age and hypothyroidism and CKD. Even within
age strata, we found significant associations between
CKD (estimated GFR <60 mL/min/1.73m2 compared
with ≥60 mL/min/1.73m2), and hypothyroidism: for per-
sons age ≤70 years, adjusted OR 1.84 (95% CI 1.08 to
3.13); for persons age >70 years, adjusted OR 1.43 (1.07
to 1.93). We did not see a statistically significant as-
sociation within age strata using multiple categories of
GFR, although these age-stratified analyses were limited
by reduced sample size in the various GFR categories.
It should be noted that 70% of individuals with GFR
<60 mL/min/1.73m2 were over 70 years of age (there
were 195/922 hypothyroid persons among all persons with
GFR <60 mL/min/1.73m2 and 41/269 hypothyroid per-
sons among those age ≤70 years with GFR <60 mL/
min/1.73m2) in the NHANES III sample.
Finally, we compared the prevalence of an elevated
TPO antibody level among persons with hypothy-
roidism at different GFR levels. The prevalence of
an elevated TPO antibody level in hypothyroid per-
sons with GFR ≥90 mL/min/1.73m2 was 56% compared
with 55% for GFR 60 to 89 mL/min/1.73m2, 55% for
GFR 45 to 59 mL/min/1.73m2, 40% for GFR 30 to
44 mL/min/1.73m2, and 40% for GFR <30 mL/min/
1.73m2. (P = 0.02 comparing elevated TPO antibody level
for persons with estimated GFR ≥45 vs. <45 mL/min/
1.73m2).
DISCUSSION
Among a nationally representative sample of adults, we
found an increased prevalence of hypothyroidism in per-
sons with reduced estimated GFR, independent of age,
gender, and race/ethnicity. In addition, with progressively
lower GFR, there was a graded, increased likelihood of
hypothyroidism.
Previous studies have suggested an increased preva-
lence of hypothyroidism in patients with ESRD requiring
maintenance dialysis, as well as an increased prevalence
of goiter [1, 2]. While numerous contributing factors have
been suggested, including altered iodine metabolism and
autoimmune thyroiditis, the exact mechanisms remain
unclear. Only one previous study has examined the preva-
lence of hypothyroidism among patients with CKD not
requiring dialysis. Among a small group of patients with
diabetic (N = 32) and nondiabetic (N = 31) nephropa-
thy (defined by urinary protein excretion greater than
0.5 g/day), 24% of study subjects had overt or subclinical
(non-autoimmune) hypothyroidism, with a higher preva-
lence among patients with diabetes [21].
Among NHANES III participants with hypothy-
roidism, only half had evidence of thyroid autoimmunity.
The association of CKD and prevalent hypothyroidism
was not confounded by concomitant type 1 diabetes (i.e.,
associated polyglandular autoimmunity), as the single
subject in NHANES III with both type 1 diabetes and
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hypothyroidism had an estimated GFR ≥90 mL/min/
1.73m2. Furthermore, we found that the frequency of ele-
vated levels of TPO antibodies was less at lower levels of
estimated GFR. Thus, our observations are not likely to
be explained by a more generalized autoimmune disorder
or syndrome.
The strengths of our study include the use of a nation-
ally representative sample of United States adults. In ad-
dition, tests performed by NHANES III were done as
screening assessments rather than for a clinical indica-
tion, and likely provide more accurate prevalence esti-
mates, which is important, given that 56% of NHANES
III participants in the hypothyroid group had subclinical
hypothyroidism based on standardized laboratory-based
criteria [9]. Our study also supports the expanding body of
evidence suggesting that metabolic and hormonal alter-
ations, as well as symptomatology and changes in quality
of life, may occur at higher GFR than has been previously
appreciated [14, 22–25].
Our study also had several limitations. While the over-
all sample was relatively large, the number of persons
with reduced GFR levels was modest, particularly in the
group with GFR <30 mL/min/1.73m2. Hence, these re-
sults are generalizable to the United States population,
but may not be completely representative of all per-
sons who receive medical care for kidney disease. In
NHANES III, GFR was estimated using serum creati-
nine concentrations in the MDRD equation, which may
be less precise at higher GFR levels, albeit less so with
the use of calibrated creatinine measurements [12]. This
is a cross-sectional study, so causality cannot be estab-
lished. However, it is unlikely that the generally mild
degrees of untreated hypothyroidism reported herein
contribute to elevated serum creatinine concentrations,
as has been reported in patients with severe untreated hy-
pothyroidism [17, 26]. Information on the presence or ab-
sence of hypothyroidism-related symptoms was also not
available. Given that only TSH and total T4 (rather than
free T4) levels were available, complete assessment of
thyroid function was not possible; however, TSH concen-
tration is considered the most sensitive indicator of hy-
pothyroidism among individuals in the absence of acute
illness [27]. Since NHANES III surveyed nonhospitalized
and noninstitutionalized persons in the United States, the
single measurement is more likely to reflect steady state
conditions. As random misclassification due to physio-
logic fluctuations in TSH and GFR levels would tend to
bias toward the null, our observations may underestimate
the true strength of association between hypothyroidism
and CKD.
CONCLUSION
We found that reduced kidney function was associated
with prevalent subclinical and clinical hypothyroidism
among ambulatory adults. Indeed, one in five persons
with estimated GFR less than 60 mL/min/1.73m2 had
laboratory or clinical evidence of hypothyroidism. Fur-
ther studies should explore potential causal mechanisms
through which CKD may be associated with increased
TSH and reduced thyroid function, including the pos-
sible roles of autoimmunity, iodine excess, and poten-
tial effects of retained solutes, such as organic acids and
guanidino compounds, on thyroid function. The roles of
clinical or subclinical hypothyroidism on physical func-
tion, cognitive function, quality of life, and depression in
CKD are unknown. However, health professionals caring
for patients with CKD should be cognizant that CKD and
hypothyroidism may exhibit overlapping symptom com-
plexes. Future investigations are needed to determine the
value of assessing or screening for clinical and subclinical
hypothyroidism among persons with CKD and ESRD.
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